Stay updated with breaking news from Randomised Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A trial investigating the gout drug colchicine as a treatment for COVID-19 has suggested it reduces the length of both supplemental oxygen therapy and hospitalisation in patients with moderate to severe COVID-19.
Share The patients were over the age of 40 and had a least one underlying health condition including obesity, diabetes or high blood pressure. Individuals over the age of 70 were able to take part whether they had an underlying health condition or not. The study looked at patients in six countries: Canada, America, Brazil, Greece, Spain and South Africa. Colchicine can have side effects, including diarrhoea, and the trial found that more patients who got the placebo reported side-effects than those who had received the drug. 'Our research shows the efficacy of colchicine treatment in prevent...
Breakthrough drugs that could change the course of COVID-19 The discovery of the effectiveness of using dexamethasone to treat the coronavirus demonstrates the power of large-scale, randomized medicine trials By Robin McKie / The Observer It remains one of the most dramatically successful outcomes in the battle against COVID-19. A cheap treatment for inflammation was found to save lives of seriously ill patients, while a trio of much-touted therapies were shown to have no effect. It is now estimated that the discovery of the effectiveness of the drug dexamethasone has saved about 650,000 li...
Azithromycin trial fails to provide evidence of benefit in COVID-19 Early on in the ongoing coronavirus disease 2019 (COVID-19) pandemic, the antibiotic azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hundreds of thousands of doses have been dispensed on this basis to treat these patients. Evidence in support of this hypothesis has been lacking, however. Now, a randomized controlled trial from the UK provides, in its preliminary findings, that it offers no clinical benefit at...
Azithromycin is an antibiotic which is known to treat inflammation in patients It had been speculated it may help people suffering with severe Covid-19 Hospitalised patients suffer inflammation as their immune system attacks itself But RECOVERY trial has now found it has no impact on chance of death, hospital stay or likelihood of needing to be put on a ventilator